The Peptide Pipeline: Key Clinical Trials to Watch in 2026

Medical Disclaimer: This article describes ongoing and planned clinical research. None of the investigational peptides discussed are FDA-approved for the indications mentioned unless explicitly stated. Clinical trial results may not translate to approved therapeutic uses. Do not use any investigational compound without consulting a licensed healthcare provider.

For most of its modern history, peptide therapeutics has been a field where animal data is plentiful, human trial data is scarce, and the distance between “promising preclinical findings” and “approved medicine” remains frustratingly wide.

2026 is an unusual year: several compounds that have been stuck in preclinical stages for years are advancing to human studies simultaneously, while others completing early-phase trials are showing results that challenge expectations. This post surveys the most significant active and upcoming trials across the compound categories readers follow most closely — including major GLP-1 pipeline developments, the first human trials for BPC-157 class compounds, and new data for neurological and longevity peptides.

GLP-1 and Beyond: The Evolving Metabolic Landscape

Retatrutide — Triple Agonist, Phase 3 (Eli Lilly)

Where semaglutide targets the GLP-1 receptor and tirzepatide adds the GIP receptor, retatrutide adds a third target: the glucagon receptor. This triple-agonist profile is designed to address a limitation of dual agonists: glucagon receptor activity promotes additional fat mobilization and thermogenic energy expenditure that GLP-1 and GIP alone don’t fully capture. The thermogenic mechanism operates in brown adipose tissue (BAT): glucagon binds GCGR (a Gs-coupled Class B GPCR) on brown adipocytes → Gs → adenylyl cyclase → cAMP → PKA. PKA activates two parallel thermogenic arms: (1) p38 MAPK pathway — PKA phosphorylates and activates MKK3/MKK6, which phosphorylate and activate p38α/β MAPK; p38 MAPK phosphorylates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1α) at Thr262/Ser265/Thr298, preventing its ubiquitin-mediated degradation and driving its transcriptional co-activation of UCP1 (uncoupling protein 1) gene expression; (2) CREB pathway — PKA phosphorylates CREB at Ser133 → pCREB binds the CRE site in the UCP1 promoter → direct transcriptional activation. Upregulated UCP1 inserts into the inner mitochondrial membrane and uncouples the proton gradient from ATP synthase — protons leak back across the inner membrane through UCP1’s proton channel rather than driving ATP synthesis → the mitochondrial electron transport chain “idles at high speed,” oxidizing fatty acids to generate heat rather than ATP (non-shivering thermogenesis). This is the same UCP1-mediated heat generation that underlies cold adaptation. For obese patients experiencing metabolic rate suppression during caloric restriction — which drives the weight loss plateau — glucagon agonism in BAT restores thermogenic drive through this GCGR/cAMP/PKA/p38/PGC-1α/UCP1 cascade, counteracting the adaptive reduction in resting energy expenditure that promotes regain.

Phase 2 results (NEJM Evidence, 2023, NCT04881760): mean weight loss of approximately 24.2% at 48 weeks at the highest dose — exceeding the approximately 20–22% seen with tirzepatide at comparable timepoints. Gastrointestinal side effects were dose-limiting, consistent with the class.

Phase 3 program: Lilly’s Phase 3 trials (NCT05959564) are evaluating cardiovascular outcomes, long-term weight maintenance, and safety at scale. Results anticipated 2027–2028.

What retatrutide won’t solve: The weight regain after discontinuation problem almost certainly applies here as well — triple agonism does not change the fundamental biology of obesity. The molecular basis for this rebound is important to understand. When GLP-1/GIP/glucagon receptor signaling is withdrawn: (1) the pharmacological bypass of leptin resistance is removed — SOCS3 still occupies the JAK2 kinase activation loop on LepRb in arcuate POMC neurons, POMC neuron leptin sensitivity remains impaired, and the arcuate appetite-suppression signal returns to its pre-drug blunted state; (2) critically, adipocyte number does not decrease during GLP-1-mediated weight loss — adipocytes shrink (lose stored triglyceride) but survive, because mature adipocytes are protected from apoptosis by chronically elevated Bcl-2 and Bcl-XL expression; after drug withdrawal, the unchanged number of now-lipid-depleted adipocytes collectively produce a leptin signal (proportional to lipid content per cell) that is far below the pre-treatment level, signaling severe energy deficit to the hypothalamus despite the body being at a lower — not unhealthy — weight; (3) the same lipid-depleted adipocytes increase ghrelin secretion from neighboring gastric oxyntic cells (signaled by low portal insulin/IGF-1) and reduce peptide YY from gut L-cells, amplifying the orexigenic drive simultaneously; (4) the metabolic rate suppression characteristic of weight loss (reduced T3/T4 conversion, reduced sympathetic tone, reduced resting energy expenditure — the T3/T4 conversion reduction has a specific enzymatic basis: falling insulin during caloric restriction reduces hepatic DIO1 (type 1 deiodinase) expression, because insulin/PI3K/Akt/SP1 signaling normally drives DIO1 transcription; simultaneously, elevated cortisol and hypoinsulinemia upregulate DIO3 (type 3 deiodinase, which inactivates T3 and converts T4 to biologically inactive reverse T3 (rT3)); the net result is that T4 is preferentially converted to rT3 rather than active T3 → the T3:rT3 ratio falls significantly → TRβ1 occupancy in skeletal muscle and brown adipose tissue drops → transcription of UCP2, UCP3, and Na⁺/K⁺-ATPase subunits declines → ATP turnover rate falls → resting energy expenditure decreases by 10–15% beyond what body mass reduction alone predicts; this adaptive thermogenesis persists after weight loss because TRβ1 occupancy only normalizes when T3 levels recover, which requires re-establishment of the insulin/DIO1 axis at a new stable body weight) persists after drug withdrawal because it is driven by the same leptin-signaling impairment, not corrected by drug cessation. The combined effect — impaired satiety signaling, orexigenic drive proportional to total adipocyte number rather than fat mass deficit, and reduced energy expenditure — creates a powerful physiological pressure to refill adipocytes to their pre-treatment lipid content, which is why regain in SURMOUNT-4 tracked toward prior body weight trajectories over 88 weeks. If SURMOUNT-4 data for tirzepatide (near-complete weight regain over 88 weeks after stopping) translates to the more potent compound, the “chronic therapy for a chronic disease” framework is even more clearly necessary.

CagriSema — GLP-1/Amylin Combination, Phase 3 (Novo Nordisk)

CagriSema combines cagrilintide (a long-acting amylin analog) with semaglutide. Amylin is a pancreatic peptide co-secreted with insulin; it reinforces satiety through central amylin receptors (area postrema and nucleus accumbens) that are distinct from GLP-1 receptor circuits. The combination exploits a different and partially non-overlapping satiety pathway.

The molecular basis for non-overlapping circuitry lies in the amylin receptor’s unusual structure: amylin receptors are obligate heterodimers composed of the calcitonin receptor (CTR) — a class B GPCR — non-covalently associated with a receptor activity-modifying protein (RAMP). Different RAMP isoforms create pharmacologically distinct receptor subtypes: CTR/RAMP1 forms the AMY₁ receptor (dominant in the area postrema and vagal afferents), CTR/RAMP3 forms AMY₃ (expressed in the nucleus accumbens and limbic system). Although both GLP-1R and amylin AMY₁/AMY₃ receptors signal through Gs/cAMP/PKA, they are expressed on distinct neuronal populations in non-identical anatomical distributions — GLP-1R satiety signaling is weighted heavily toward the arcuate nucleus/hypothalamic POMC circuit and brainstem NTS neurons, while amylin’s dominant satiety action originates in area postrema neurons projecting to the NTS and lateral parabrachial nucleus. The partial circuit non-overlap explains why the combination (CagriSema) achieves greater weight loss than either component alone: the two compounds engage complementary neural populations, producing additive reduction in energy intake rather than saturation of a shared downstream node. This also explains the clinical observation that patients with attenuated GLP-1 response (due to GLP-1R polymorphisms or receptor downregulation) may retain full response to the amylin component.

REDEFINE 1 Phase 3 results (2025): 22.7% mean weight loss at 68 weeks — numerically superior to semaglutide monotherapy and approaching tirzepatide efficacy. Notably, cagrilintide as a standalone compound had modest weight loss effects (~5–8%); the combination’s magnitude suggests synergy, not merely additive effects.

Why this matters for the peptide field: CagriSema demonstrates that targeting multiple hormonal satiety systems simultaneously — beyond GLP-1/GIP — produces additional efficacy. This validates the multi-target approach and suggests that the GLP-1 receptor alone is not the final word in satiety pharmacology. The molecular basis for the synergy exceeding simple additivity (~22.7% vs. the ~20% expected from adding 5% cagrilintide monotherapy to 15% semaglutide monotherapy) lies in temporal complementarity between the two satiety circuits. GLP-1R agonism by semaglutide produces its peak satiety signal during and immediately post-meal: vagal GLP-1R afferents in the portal vein and gut wall activate NTS neurons within minutes of meal initiation, and semaglutide’s GLP-1R occupancy sustains this signal through the immediate post-meal period. However, as the inter-meal interval extends, the hypothalamic satiety signal from GLP-1R inputs decays as NPY/AgRP neurons in the arcuate nucleus gradually rebound — the “late inter-meal hunger resurgence” that typically drives early caloric intake before the next scheduled meal. Amylin’s CTR/RAMP1 and CTR/RAMP3 (AMY1, AMY3) Gs/cAMP pathway in area postrema neurons operates on a different temporal window: cagrilintide’s 168-hour half-life maintains sustained CTR/RAMP occupancy throughout the full inter-meal period, and the area postrema → NTS → parabrachial nucleus → hypothalamic paraventricular nucleus relay sustains satiety tone precisely during the window when semaglutide’s effect is fading. Because the GLP-1R afferent satiety arc (peak early, decays through the inter-meal period) and the amylin CTR/RAMP arc (sustained throughout the inter-meal period) are temporally non-overlapping in their dominant contribution, the combination provides near-continuous suppression of appetite across the full 24-hour inter-meal cycle rather than two overlapping peaks covering the same post-meal window. The 22.7% vs. ~20% expected synergy most likely reflects this coverage of the late inter-meal hunger window that single-agent semaglutide cannot sustain, reducing total daily caloric intake through prevention of opportunistic between-meal eating rather than increased peak post-meal satiety. Amylin analogs may also have different lean mass effects than pure GLP-1 agents, which is under active investigation.

Timeline: NDA submission anticipated in late 2026; approval possible 2027.

Amycretin — GLP-1/Amylin Single Molecule, Phase 2 (Novo Nordisk)

Amycretin is a single-molecule co-agonist of GLP-1 and amylin receptors — the same dual mechanism as CagriSema but engineered into one compound rather than a combination product. Phase 1 oral results published in 2024 showed 13.1% weight loss at 12 weeks — a striking early signal for a 12-week endpoint (most 12-week results for GLP-1 monotherapy show 4–8% loss).

Phase 2 subcutaneous formulation studies are ongoing. The subcutaneous formulation is expected to show substantially higher efficacy than the oral Phase 1 results.

What makes amycretin scientifically interesting: The concept of combining GLP-1 and amylin receptor activity in a single molecule eliminates the formulation and administration challenges of combination products. If the subcutaneous Phase 2 data confirms the Phase 1 signal, amycretin represents a next-generation approach that could potentially replace CagriSema clinically.

Oral GLP-1 Pipeline: Beyond Oral Semaglutide

The success of oral semaglutide 50mg (OASIS-1 trial: 15.1% weight loss — comparable to injectable semaglutide 1mg, PMID:37742727) has validated the oral peptide delivery concept and triggered a wave of oral-route GLP-1 development.

Orforglipron (Eli Lilly) — the most advanced oral non-peptide GLP-1 receptor agonist. Unlike semaglutide, orforglipron is a small molecule that activates the GLP-1 receptor without being a peptide itself. To appreciate why this matters mechanistically, consider how peptide agonists engage the GLP-1 receptor — a class B GPCR with a large extracellular domain (ECD). Peptide agonists (GLP-1, semaglutide, liraglutide) follow a two-step binding model: the C-terminal α-helix of the peptide docks to the ECD in the first recognition step, then the flexible N-terminal segment threads down into the transmembrane (TM) bundle core, contacting TM1, TM2, TM3, TM5, and ECL1/ECL2 residues that drive Gαs coupling and adenylyl cyclase activation → elevated cAMP → PKA → insulin secretion and satiety signaling (PMID:28705497). This two-step mechanism requires a structurally intact peptide backbone — it cannot be replicated by a small molecule and cannot survive oral gastric proteolysis without chemical modification (the fatty-acid chain on semaglutide provides albumin binding that partially protects it, but it still requires the SNAC absorption enhancer and fasting conditions to cross the gastric mucosa before proteolytic degradation occurs). Orforglipron bypasses this constraint entirely. As a non-peptide small molecule, it binds directly within the TM allosteric pocket — the same transmembrane bundle interior that the peptide N-terminus occupies in step two — without any ECD contact. This TM-only binding achieves full Gαs agonism (verified by cAMP and β-arrestin recruitment assays in HEK293 cells expressing human GLP-1R), despite lower absolute affinity than native GLP-1, because receptor efficacy is determined by the TM activation microswitch (toggle switch triad: W296-F307-Y241), not ECD engagement. The practical consequence: orforglipron is orally bioavailable without SNAC, without fasting, and without food restriction requirements — because it is not subject to gastric peptidase degradation in the first place (PMID:35320700). Phase 2 results: 9–12% weight loss at 26 weeks, with Phase 3 cardiovascular and obesity trials underway (NCT05536232). The key advantage: no food restriction required for absorption (oral semaglutide must be taken fasting, with limited water, and patient waits 30 minutes before eating). If approved, orforglipron could substantially expand oral access.

Danuglipron (Pfizer) — oral GLP-1 small molecule, Phase 3. The twice-daily formulation that advanced through Phase 2 produced dose-limiting nausea and vomiting at efficacious doses, reflecting a PK-driven tolerability constraint shared by the oral GLP-1 small molecule class. The mechanism: GLP-1R-mediated gastrointestinal side effects are primarily Cmax-driven — proportional to the peak plasma concentration at each dosing event — rather than AUC-driven (proportional to total drug exposure). The area postrema (which samples systemic blood through fenestrated capillaries that lack tight-junction blood-brain barrier protection) and the nucleus tractus solitarius express dense GLP-1R; these neurons respond to the rate of receptor occupancy change during the Cmax rise with a proportionally larger activation of the nausea-emesis circuit than they do to sustained moderate occupancy. The downstream emetic signal propagates via 5-HT3 receptor activation on NTS-to-DMV projections (explaining why ondansetron attenuates the response) and NK1R-mediated Substance P release at the NTS → motor program of gastric dysrhythmia and vomiting. A twice-daily formulation delivers two Cmax peaks per 24 hours, generating two acute area postrema activation transients — each capable of triggering this circuit above the emesis threshold. Reformulating to a once-daily modified-release (XR) profile extends absorption over 6–12 hours rather than 1–3 hours: same total daily AUC, substantially reduced Cmax per dosing event → area postrema activation transient stays below dose-limiting threshold while cumulative receptor exposure drives the metabolic efficacy. This Cmax-vs-AUC tolerability decoupling is the same pharmacokinetic principle used to improve gastrointestinal tolerability of metformin extended-release over immediate-release. Phase 3 data for the once-daily formulation is pending, with weight loss expected in the 9–14% range based on Phase 2 PD modeling.

Why the oral pipeline matters: Injectable peptides create access barriers — cost, injection phobia, cold-chain storage requirements. Oral formulations that match or approach injectable efficacy would dramatically expand the number of patients who use GLP-1 medications, with major implications for the compounded GLP-1 market and telehealth platforms.

GLP-1 and Addiction: NIDA-Funded Trials

The mesolimbic mechanism of GLP-1 receptors — GLP-1Rs expressed in the VTA and nucleus accumbens attenuate dopamine release in response to rewarding stimuli — creates a biological rationale for GLP-1 drugs in addiction medicine. The cellular mechanism is now reasonably well characterized: GLP-1Rs are expressed predominantly on GABAergic interneurons within the VTA rather than on dopamine projection neurons themselves. GLP-1R activation couples to Gs → adenylyl cyclase → elevated cAMP → PKA → increased GABAergic interneuron firing rate. The heightened GABA release onto adjacent dopamine neurons activates both GABA-A receptors (ionotropic Cl⁻ channels → membrane hyperpolarization) and GABA-B receptors (metabotropic Gi/Go → Gβγ → GIRK K⁺ channel opening → further hyperpolarization), reducing dopamine neuron action potential frequency. The downstream result is attenuated phasic dopamine release in the nucleus accumbens shell — the transient that encodes reward salience and drives cue-reactivity craving. Because the same NAc dopamine signal mediates the rewarding properties of alcohol, opioids, and cocaine, a single receptor mechanism can theoretically blunt the motivational pull of multiple substance classes (PMID:23954401). Multiple trials are underway:

Alcohol use disorder (STAR-AUD): A NIDA-funded multisite trial evaluating semaglutide vs. placebo in adults with alcohol use disorder. Primary outcome: reduction in heavy drinking days at 16 weeks. Early data from smaller studies shows meaningful reductions in alcohol craving and consumption; STAR-AUD will provide the definitive controlled evidence. Results expected 2026.

Opioid use disorder: An NIH-funded trial evaluating GLP-1 treatment as adjunct to standard opioid use disorder treatment (buprenorphine maintenance). The rationale involves attenuating the cue-reactivity component of craving that opioid substitution alone doesn’t address. The mechanistic distinction between buprenorphine’s target and GLP-1R’s target clarifies why combination therapy is plausibly additive rather than redundant. Buprenorphine is a partial agonist at the μ-opioid receptor (MOR): MOR/Gαi → inhibited adenylyl cyclase → reduced cAMP → Gβγ-mediated GIRK K⁺ channel activation → membrane hyperpolarization and reduced Ca²⁺ influx in locus coeruleus and ventral striatum neurons → attenuated spontaneous withdrawal symptoms and homeostatic craving driven by opioid receptor upregulation from chronic opioid exposure. This addresses the physical dependence craving — the basal, spontaneous craving that exists even in the absence of opioid-associated environmental triggers. What buprenorphine does not address is cue-reactivity craving — the conditioned incentive salience triggered by people, places, objects, and emotional states previously associated with opioid use. The neurobiology of cue-reactivity runs through the mesolimbic dopamine system: drug-associated cues → basolateral amygdala → VTA dopamine neuron activation → phasic dopamine burst → nucleus accumbens shell dopamine transient → conditioned approach motivation and craving. Buprenorphine acts at opioid receptors and does not directly suppress this conditioned dopamine circuit. GLP-1R agonism does: GLP-1Rs on VTA GABAergic interneurons → Gs/cAMP/PKA → elevated interneuron excitability → increased GABA release onto dopamine projection neurons → GABA-A (Cl⁻ → hyperpolarization) and GABA-B (Gβγ → GIRK K⁺ → further hyperpolarization) → attenuated phasic dopamine burst amplitude to opioid-associated cues → weakened conditioned incentive salience → reduced cue-triggered relapse drive. The two treatments therefore act on molecularly non-overlapping craving circuits — MOR/Gαi/GIRK addressing homeostatic/withdrawal craving vs. GLP-1R/Gs/GABAergic interneuron/dopamine phasic burst addressing cue-reactivity craving — which is the molecular basis for the hypothesis that combination therapy may suppress both craving dimensions simultaneously, achieving efficacy beyond what either agent achieves alone.

Cocaine use disorder: Observational data from large retrospective databases showing reduced cocaine use disorder treatment admissions in patients on GLP-1 drugs has prompted prospective trial design. No large Phase 3 has reported yet, but this is among the most active areas of addiction pharmacology research. The cocaine indication is mechanistically distinct from alcohol and opioids in ways that inform why GLP-1 may still work through the same GLP-1R/VTA GABAergic circuit while engaging it at a different step.

Cocaine’s pharmacology differs fundamentally from alcohol and opioids: cocaine is a dopamine transporter (DAT) blocker — it binds the outward-facing conformation of DAT (SLC6A3), a Na⁺/Cl⁻-dependent monoamine transporter, via its tropane nitrogen occupying the substrate-binding S1 site → blocks DAT’s conformational cycle → prevents DA reuptake from the synaptic cleft → DA accumulates at NAc medium spiny neuron synapses. The degree of NAc DA accumulation (and thus the subjective “high” intensity) is determined by two quantities simultaneously: the fraction of DAT blocked (cocaine dose-dependent) and the rate of presynaptic DA release from VTA terminals. The GLP-1R mechanism directly addresses the second quantity. GLP-1R agonist → GLP-1Rs on VTA GABAergic interneurons → Gs/cAMP/PKA → elevated interneuron excitability → increased tonic GABA release onto VTA dopamine projection neurons → GABA-A (Cl⁻ influx → hyperpolarization) + GABA-B (GIRK K⁺ → further hyperpolarization) → reduced VTA dopamine neuron basal and phasic firing rate → lower presynaptic DA release into the NAc synapse. When cocaine subsequently blocks DAT, it prevents reuptake of a reduced DA flux rather than the full unblocked flux — the absolute NAc DA accumulation is attenuated even though DAT blockade is complete. This is distinct from opioid cue-reactivity, where the issue is conditioned phasic bursts in the context of normal baseline function; for cocaine, GLP-1R agonism acts on the presynaptic supply term of a DAT-blockade equation. The absence of an established pharmacotherapy for cocaine use disorder (no equivalent of buprenorphine for opioids) also explains why prospective Phase 3 trial design is more complex: there is no comparator arm, endpoints must be validated de novo, and the FDA has no precedent pathway for cocaine use disorder approval. Phase 3 trial designs are in protocol development stage as of 2026.

The potential significance: If GLP-1 drugs prove effective for substance use disorders — not just obesity — it would represent an entirely new indication category, dramatically expanding prescribing volume and potentially reshaping the addiction medicine field. The compounding and peptide community should watch these trials closely.

SPARK: Oral Semaglutide in Parkinson’s Disease (Phase 2)

The SPARK trial is evaluating oral semaglutide (OG 3mg) in early Parkinson’s disease patients. As covered in the GLP-1 brain health guide, the neuroprotective rationale for GLP-1 therapy in Parkinson’s disease is supported by the exenatide trials — particularly the 3-year post-trial persistence of motor advantage suggesting possible disease-modifying rather than purely symptomatic effect. Three mechanistically distinct pathways converging on dopaminergic neuron survival provide the biological basis for this possibility. Neuroinflammation suppression: GLP-1Rs expressed on microglia — the brain’s resident immune cells, which become chronically activated by α-synuclein aggregates and NLRP3 inflammasome signaling from dying dopamine neurons — couple to Gs/cAMP/PKA → PKA phosphorylates and inactivates IKKβ → IκBα is not phosphorylated or degraded → NF-κB (p65/p50) remains cytoplasmic → reduced transcription of TNF-α, IL-1β, and iNOS → reduced ROS/peroxynitrite production → attenuated nitration of α-synuclein tyrosine residues (which accelerates fibril formation and Lewy body accumulation). This breaks the self-amplifying cycle in which dying neurons → microglial activation → more ROS → more neuron death. LRRK2-mediated lysosomal restoration: LRRK2 (leucine-rich repeat kinase 2) — the most common hereditary PD risk gene and broadly elevated in sporadic PD — hyperphosphorylates Rab GTPases (Rab8A at Thr72, Rab10 at Thr73) → phospho-Rabs are displaced from lysosomal membranes → macroautophagy and chaperone-mediated autophagy of α-synuclein is impaired → Lewy body accumulation. GLP-1R/Gs/cAMP/PKA → PKA phosphorylates LRRK2 at Ser935 → pSer935-LRRK2 recruits 14-3-3 chaperone proteins that conformationally sequester the kinase → reduced Rab phosphorylation → lysosomal trafficking restored → α-synuclein cleared before aggregation (PMID:28422128). Direct dopamine neuron trophic support: GLP-1R on substantia nigra pars compacta dopaminergic neurons → Gs/cAMP → PKA → CREB Ser133 phosphorylation → BDNF promoter CRE activation → BDNF/TrkB → PI3K/Akt → BAD Ser136 phosphorylation (anti-apoptotic) + mTORC1 ribosome biogenesis. PKA simultaneously activates Bcl-2 gene transcription → elevated Bcl-2/Bcl-xL protein → preserved mitochondrial outer membrane integrity → cytochrome c retained → caspase-9/caspase-3 cascade does not initiate in stressed dopamine neurons. These three arms explain why the exenatide motor advantage persisted 36 months after drug discontinuation in the 2020 Athauda et al. follow-up: neuroinflammation suppression reduces ongoing SN tissue loss, LRRK2/lysosomal restoration reduces pathological protein burden, and BDNF/Bcl-2 trophic support extends the survival window of already-damaged dopamine neurons.

SPARK uses oral semaglutide for practical reasons (regulatory familiarity, existing approval), targeting an early PD population in whom disease modification could have the greatest impact. Primary endpoints include DaTscan dopaminergic imaging and UPDRS motor scoring. Trial completion expected in late 2026 with results possibly in 2027.

Why this is among the most watched neurological trials in progress: An effective disease-modifying treatment for Parkinson’s does not currently exist. If SPARK shows meaningful slowing of dopaminergic neuronal loss, it would represent one of the most significant neurological therapeutics advances of the decade — and would be built on a peptide class.

Tissue Repair: The First Human BPC-157 Trial

Synthetic BPC-157 Analog — Phase 1, IBD Indication

A European biotech group submitted a Phase 1 IND in late 2025 for a synthetic BPC-157 analog — modified from the original sequence (GEPPPGKPADDAGLV) to improve oral bioavailability and stability — targeting inflammatory bowel disease. Enrollment at sites in Germany and Croatia is expected to begin in mid-2026.

Why the compound modification matters: The synthetic analog differs from the standard BPC-157 sequence that circulates in the research chemical market. Results from this trial will not directly validate the unmodified preparations most commonly self-administered. However, even an analog trial represents the first controlled human pharmacokinetics and safety data for a BPC-157-class compound.

What Phase 1 will establish: Safety and tolerability at escalating doses; human pharmacokinetics (how the compound is absorbed, distributed, metabolized, eliminated — data that is entirely absent for BPC-157 in humans); whether the drug behaves as animal models predict. Phase 1 does not evaluate efficacy.

Current regulatory status reminder: The original BPC-157 sequence remains on the FDA’s prohibited compounding list in the US. That status is unlikely to change based on Phase 1 data from a modified analog in a European trial. However, positive Phase 1 data would provide a scientific argument for a US IND application on the compound class.

IBD as strategic first indication: IBD (Crohn’s disease and ulcerative colitis) represents a strong target for BPC-157 class compounds — the preclinical data on gut mucosal healing is among the most consistent in the BPC-157 literature, and IBD patients with refractory disease represent a high unmet need population. This is strategically astute trial design.

Ophthalmic: TB-500 Fragment Reaches Phase 2

RGN-259 (Thymosin Beta-4 Ophthalmic Solution) — Phase 2

RegeneRx Biopharmaceuticals is advancing RGN-259, a thymosin beta-4 ophthalmic solution, in Phase 2 for neurotrophic keratopathy — a corneal disease caused by impaired trigeminal nerve function that results in progressive corneal damage.

Thymosin Beta-4’s mechanism in corneal healing involves the same core actin-sequestration and cell migration promotion that operates in systemic wound healing, but the molecular details are worth spelling out because the corneal application is unusually well-matched to this specific mechanism. Tβ4 binds G-actin monomers through its WH2 (WASP-homology 2) domain — specifically the sequence L-K-K-T-E-T-Q at residues 17–23, which inserts into the hydrophobic cleft at the barbed-end face of actin near the nucleotide-binding pocket. This 1:1 Tβ4/G-actin complex prevents spontaneous F-actin nucleation by sequestering actin monomers away from both barbed-end elongation and Arp2/3-independent nucleation events. In a healing corneal epithelium, where SDF-1α (CXCL12) is released from the injured stromal fibroblasts and the inflammatory cell infiltrate at the wound margin, CXCR4 receptors on migrating corneal epithelial cells engage Gαi → PI3K-γ (p110γ/p101 heterodimer) → PIP₃ accumulation at the leading-edge plasma membrane → Rac1 activation (via DOCK2/ELMO1 and TIAM1 guanine nucleotide exchange factors) → Rac1-GTP → WAVE2/Arp2/3 complex → branched dendritic actin network at the lamellipodia leading edge → epithelial cell migration toward the wound. The critical insight for why Tβ4 specifically helps this process: Arp2/3-mediated branching creates new barbed-end nucleation sites with a very high local affinity for actin monomers — the PIP₃-rich leading-edge environment creates a “sink” for G-actin that transiently exceeds Tβ4’s binding affinity for G-actin, releasing sequestered actin monomers precisely at the barbed ends where Arp2/3 is branching. Tβ4 thus acts as a regulated actin monomer buffer — preventing non-directed polymerization everywhere in the cytoplasm while allowing directed polymerization specifically at the Arp2/3/WAVE2-activated lamellipodia edge. The corneal application is particularly well-matched because the cornea is avascular (no blood supply) and heals without the leukocyte-mediated granulation tissue formation that dominates vascularized wound healing. The corneal epithelial cells must migrate across the denuded stroma using their own cytoskeletal machinery — there is no neovascularization component to recruit or scaffolding deposited by macrophages. This makes the epithelial migration arm that Tβ4 directly supports the primary healing mechanism, rather than one contributor among several as it is in skin or muscle repair (Sosne et al., 2004, PMID:15119837).

Regulatory implications: An FDA-approved thymosin beta-4 product would establish human safety data at the highest regulatory standard. A “Reference Listed Drug” designation creates both opportunity (evidence base for compounding applications) and constraint (compounding pharmacies would need to demonstrate medical necessity for deviation from the approved product).

Phase 3 planning: Positive Phase 2 results would trigger Phase 3 design. A regulatory decision for RGN-259 is years away, but this is the TB-4 compound class’s closest approach to an FDA approval as of 2026.

Mitochondrial-Derived Peptides: Clinical Development Begins

MOTS-c Analog (CB5945) — Phase 1

Cohbar Inc. has an IND application for CB5945, a mitochondrial-derived peptide analog incorporating elements of the MOTS-c mechanism. MOTS-c, encoded in mitochondrial DNA, activates AMPK and SIRT1 pathways that improve insulin sensitivity and metabolic function — an “exercise mimetic” that produces physiological effects resembling those of physical training without the muscle contraction.

Phase 2 animal data showed significant improvements in insulin resistance and fat mass in obese rodent models. Phase 1 in humans will answer whether the compound is tolerable and whether the animal pharmacological profile translates to human physiology.

How MOTS-c Activates AMPK: The Folate Cycle Mechanism

MOTS-c’s mechanism of AMPK activation is indirect — and the pathway explains at a molecular level why it earns the “exercise mimetic” label.

MOTS-c is a 16-amino acid peptide (MRWQEMGYIFYPRKLR) encoded within the 12S rRNA gene of mitochondrial DNA. Its 2015 discovery (Lee et al., PMID: 25738459) challenged the longstanding assumption that mitochondrial DNA exclusively encodes respiratory chain proteins, transfer RNAs, and ribosomal RNAs — demonstrating that the mitochondrial genome also produces bioactive signaling peptides.

The path from mitochondrial DNA to nuclear action — MOTS-c’s synthesis, export, and nuclear translocation: MOTS-c is translated in the mitochondrial matrix by mitochondrial ribosomes using the mitochondrial genetic code — in which UGA encodes tryptophan (rather than acting as a stop codon as in the universal code), enabling readthrough of the short open reading frame embedded within the 12S rRNA transcript to yield the MRWQEMGYIFYPRKLR peptide. Under baseline metabolic conditions, MOTS-c is predominantly retained within the mitochondria. Under metabolic stress — nutrient deprivation, reactive oxygen species elevation, or the energetic demand of sustained exercise — the inner mitochondrial membrane potential (ΔΨm) fluctuates and mitochondrial fission dynamics change. This stress-driven shift in mitochondrial membrane physiology is proposed to facilitate MOTS-c release from the matrix into the cytoplasm, potentially through VDAC (voltage-dependent anion channel) in the outer mitochondrial membrane, which can gate small solutes (~5 kDa) under partially open conformational states; the precise export mechanism remains an open question in MOTS-c biology. Once in the cytoplasm, MOTS-c’s C-terminal basic patch — Pro12-Arg13-Lys14-Leu15-Arg16 (PRKLR) — resembles a classical nuclear localization signal (NLS). This NLS is recognized by importin-α (KPNA family members) → importin-α recruits importin-β (KPNB1) → the trimeric cargo-importin-α/β complex docks at the cytoplasmic face of the nuclear pore complex (NPC) via importin-β/FG-repeat-nucleoporin interactions → Ran-GTP (abundant in the nuclear interior) binds importin-β → conformational change that releases MOTS-c into the nucleoplasm. Truncation and mutation experiments confirmed NLS dependence: deletion of the C-terminal PRKLR sequence abolished nuclear accumulation under stress conditions. This importin-α/β/RanGTPase mechanism is the same used by canonical nuclear proteins — what makes MOTS-c exceptional is not the import mechanism but the origin of the cargo: a signaling peptide synthesized entirely by the mitochondria’s own ribosomal machinery, using a divergent genetic code, acting as a metabolic regulator in the nuclear compartment. This mitochondria-to-nucleus signaling — termed mitochondrial retrograde signaling — represents a cellular communication channel through which the energetic state of the mitochondria directly instructs nuclear gene expression programs.

Under metabolic stress, MOTS-c translocates to the nucleus and disrupts folate cycle metabolism: it inhibits AICAR transformylase (ATIC) — the bifunctional enzyme that catalyzes both the penultimate step of de novo purine synthesis (transfer of a formyl group from 10-formyl-tetrahydrofolate (10-formyl-THF) onto AICAR’s 5-amino group, yielding formyl-AICAR (FAICAR)) and the final cyclization (FAICAR → IMP). ATIC’s formyltransferase active site coordinates 10-formyl-THF via contacts with its pteroyl and glutamate-tail moieties to position the formyl group for nucleophilic transfer; MOTS-c occupies this binding site in a way that prevents 10-formyl-THF from accessing the active site, halting the formyl transfer and leaving AICAR unable to progress to FAICAR. MOTS-c additionally inhibits MTHFS (5,10-methenyl-tetrahydrofolate synthetase), which generates the upstream 5,10-methenyl-THF intermediate needed to regenerate 10-formyl-THF — further restricting cofactor replenishment and amplifying AICAR accumulation beyond what ATIC inhibition alone would produce. With both enzymes inhibited, AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) builds up intracellularly and activates AMPK by binding the CBS3 regulatory site on AMPK’s γ-subunit — the AMP-sensing exchange site — displacing inhibitory ATP and stabilizing AMPK in an active conformation that is additionally resistant to PP2A-mediated Thr172 dephosphorylation, producing sustained AMPK activity that mimics the AMP:ATP ratio shift that signals cellular energy depletion.

Activated AMPK then drives the downstream cascade:

Increases intracellular NAD⁺ (by suppressing anabolic ATP-consuming pathways) → activates the NAD⁺-dependent deacetylase SIRT1
SIRT1 deacetylates and activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1α) — the master transcriptional regulator of mitochondrial biogenesis, fatty acid β-oxidation, and glucose uptake gene programs
AMPK directly phosphorylates acetyl-CoA carboxylase (ACC) → reduces malonyl-CoA → disinhibits CPT1 → enhanced mitochondrial fatty acid import and oxidation

The “exercise mimetic” characterization reflects this shared pathway: intense exercise depletes ATP → AMP:ATP ratio rises → AMPK activation → PGC-1α → mitochondrial adaptations. Exercise also increases circulating MOTS-c levels (Cataldo et al., 2022, PMID: 35545484) — suggesting MOTS-c is part of the physiological signaling cascade through which exercise produces systemic metabolic benefits. Exogenous MOTS-c (or the CB5945 analog) supplements this endogenous signal without requiring muscle contraction. Whether this mechanism faithfully reproduces all benefits of exercise in humans — including cardiovascular adaptations and bone density effects that involve mechanical loading — is not established; AMPK/PGC-1α activation represents a subset of exercise’s biology: specifically, the metabolic and mitochondrial adaptations that depend on energetic stress are captured, but three categories of exercise benefit require physical loading that MOTS-c cannot substitute — (1) bone density: repetitive mechanical strain activates integrin-α5β1/FAK → YAP/TAZ nuclear translocation → TEAD transcriptional activation → scleraxis/COL1A1/osteocalcin expression, while the resulting micro-damage triggers Wnt/β-catenin → RUNX2/SP7/osteoblast differentiation; LOX-mediated pyridinoline crosslinking that confers bone matrix stiffness also requires repetitive strain-induced remodeling cycles that a circulating peptide cannot initiate; (2) cardiac hypertrophy and coronary angiogenesis: chronic sympathetic β₁-AR/cAMP/PKA activation during sustained cardiovascular exercise drives eccentric ventricular hypertrophy via calcineurin/NFAT/GATA4, while the accompanying myocardial oxygen demand triggers VEGF-A/VEGFR2/PI3K/eNOS-driven coronary capillary angiogenesis — adaptations contingent on cardiac pressure load and mechanical wall stress that circulating MOTS-c does not generate; (3) skeletal muscle hypertrophy: mTORC1 activation by MOTS-c proceeds through AMPK/nutrient sensing, but myofibrillar protein synthesis for structural hypertrophy requires the parallel mechanical branch — titin-FAK/ILK phosphorylation → MEK/ERK activation → mechano-growth factor (MGF) splice-variant of IGF-1 → PI3K/Akt/mTORC1 — plus satellite cell activation via hepatocyte growth factor (HGF)/c-Met/MyoD that requires eccentric-contraction-induced membrane disruption and basement membrane remodeling to progress to myonuclear fusion and net fiber cross-section gain.

The bigger picture: MOTS-c’s mechanism — mitochondrial DNA encoding a peptide that regulates metabolism — represents a genuinely novel biology that differs from classical endocrine peptide targets. If Phase 1 demonstrates human safety and pharmacological activity, it would open a new category of metabolic therapeutics distinct from GLP-1, GIP, and GH-axis agents.

Humanin Analog (HNG) — Phase 1 Safety Study

Humanin, first identified from mitochondrial DNA in the early 2000s, has shown effects on neuronal protection (particularly in Alzheimer’s disease models), insulin sensitivity, and cardiovascular function in animal studies. A humanin analog (HNG — modified for enhanced potency) is in Phase 1 at the USC Leonard Davis School of Gerontology in healthy older adults, characterizing pharmacokinetics and establishing safety.

Humanin’s receptor biology is unusually complex and partly explains why it has attracted longevity research interest. Unlike most signaling peptides that bind single GPCRs, humanin acts on a tripartite heterodimeric receptor complex consisting of: gp130 (IL-6 signal transducing subunit, also known as CD130), CNTFRα (ciliary neurotrophic factor receptor alpha), and WSX-1 (also called IL-27Rα). This same receptor complex is used by CNTF and cardiotrophin-like cytokine — placing humanin within an unusual cytokine receptor superfamily for a mitochondrially-encoded peptide. Humanin binding to this tripartite complex → JAK1 and JAK2 transphosphorylation → STAT3 Tyr705 phosphorylation → STAT3 dimerization → nuclear translocation → binding to STAT3-response elements in promoters of anti-apoptotic genes including Bcl-2, BCL-XL, and Mcl-1 → increased expression of these pro-survival proteins → elevated apoptotic threshold in neurons, cardiomyocytes, and pancreatic beta cells (Minami et al. 2003, PMID:12526792).

A second, intracellular mechanism operates independently of the surface receptor. At the subcellular level, humanin enters cells and directly interacts with the proapoptotic protein Bax — specifically binding Bax’s BH3 domain, the same region that PUMA and BID use to activate Bax. By occupying the BH3 binding groove, humanin prevents Bax conformational change, membrane insertion, and oligomerization in the mitochondrial outer membrane → cytochrome c release is blocked → the intrinsic caspase-9/caspase-3 apoptotic cascade cannot initiate. In Alzheimer’s-relevant neurons, humanin additionally binds and neutralizes IGFBP3 (insulin-like growth factor binding protein 3). IGFBP3 normally circulates bound to IGF-1/IGF-2, but in the amyloid-beta-exposed neuronal environment, amyloid-beta oligomers upregulate IGFBP3 expression and promote its intracellular accumulation, after which IGFBP3 activates apoptosis through a mechanistically distinct route that does not require Bax or the intrinsic mitochondrial pathway. The BAX-independent pathway proceeds as follows: IGFBP3 contains a C-terminal nuclear localization signal (NLS) that interacts with the endocytic receptor megalin/LRP2 on the neuron surface and with importin-β in the cytoplasm → IGFBP3 is translocated into the nucleus. Once nuclear, IGFBP3’s N-terminal domain physically binds RXRα (retinoid X receptor alpha) — a nuclear receptor that normally heterodimerizes with RAR, VDR, TR, and PPAR family members to regulate transcription at retinoic acid response elements (RAREs). The IGFBP3/RXRα complex occupies RARE-containing promoters and redirects RXRα transcriptional activity toward a pro-apoptotic gene program that includes upregulation of caspase-activating factors and suppression of RXRα’s normal pro-survival PPAR-driven transcription → caspase activation and neuronal apoptosis proceeds entirely downstream of nuclear transcription, bypassing the Bax/cytochrome c/caspase-9 axis. This pathway is particularly consequential in post-mitotic neurons because mature neurons maintain high constitutive BCL-2 and BCL-XL expression — partly suppressing the classical Bax-mediated intrinsic pathway — which means the IGFBP3/RXRα nuclear route can be the dominant apoptotic mechanism in amyloid-beta-stressed neurons even when Bax-mediated cytochrome c release is attenuated. Humanin’s high-affinity binding to IGFBP3 in the cytoplasm sequesters IGFBP3 before it can reach the nucleus, physically preventing megalin/importin-β-mediated nuclear import → the IGFBP3/RXRα complex never forms → this alternate caspase-activation program is blocked. This IGFBP3 neutralization therefore closes an apoptotic route that the JAK1/JAK2/STAT3/Bcl-2 arm (which elevates the threshold for Bax activation) does not directly address, explaining why humanin provides broader neuronal protection than any single anti-apoptotic mechanism would predict. Together, the JAK/STAT3 survival gene induction, Bax sequestration, and IGFBP3 neutralization represent three mechanistically distinct anti-apoptotic actions in the same cell — which is why humanin demonstrates broad cytoprotective effects across neurodegenerative, metabolic, and cardiovascular disease models, despite operating from the mitochondrial genome rather than the nucleus.

This trial represents the first controlled human data on mitochondrial-derived longevity peptides. Humanin is not accessible outside of a clinical trial context — it is not compounded and is not available on the research chemical market. The scientific significance for longevity biology is substantial; if HNG demonstrates pharmacological activity consistent with animal findings, it would validate a genuinely new class of longevity-targeting compounds.

First cohort results expected to be presented at a geroscience conference in late 2026.

Reproductive Hormones: Kisspeptin Human Trial Advances

Kisspeptin Intranasal — Hypothalamic Amenorrhea (UK/US)

Kisspeptin (a 54-amino acid peptide) is the upstream regulator of the reproductive GnRH/LH/FSH axis. Kisspeptin neurons in the hypothalamus gate the entire reproductive hormone cascade; kisspeptin deficiency is the mechanism behind hypothalamic amenorrhea — period loss due to energy deficit, over-exercise, or chronic stress.

A 2025 trial by Mills and colleagues demonstrated that intranasal kisspeptin delivery could restore LH pulsatility in women with hypothalamic amenorrhea — the first evidence that non-injected delivery can activate the reproductive axis (PMID:40215751). Understanding the molecular mechanism clarifies why kisspeptin can restore pulsatile LH rather than simply increasing tonic levels. Kisspeptin binds Kiss1R (GPR54), a Gq/G11-coupled GPCR expressed specifically on the surface of GnRH neurons in the arcuate nucleus (ARC) and anteroventral periventricular nucleus (AVPV) of the hypothalamus. Kiss1R/Gq → PLCβ → IP₃ + DAG → IP₃ binds IP₃R on the GnRH neuron’s endoplasmic reticulum → Ca²⁺ release into the cytoplasm → simultaneously, DAG → PKC → phosphorylates and opens TRPC (transient receptor potential canonical) channels at the plasma membrane → non-selective cation influx. The combination of intracellular Ca²⁺ release and TRPC-mediated membrane depolarization drives GnRH neurons to fire action potentials that propagate down axonal projections to nerve terminals in the median eminence → each action potential triggers Ca²⁺-dependent exocytosis of GnRH-containing dense-core vesicles into the hypothalamo-pituitary portal capillaries → portal GnRH pulse → anterior pituitary GnRHR activation (Gq-coupled on gonadotrophs) → PLCβ/IP₃/Ca²⁺ → LH (and FSH) exocytosis into systemic circulation. Because kisspeptin drives GnRH neuron action potentials rather than modulating GnRH gene transcription, it generates pulsatile LH secretion — mimicking the normal neuroendocrine oscillator rather than producing a flat sustained elevation. In hypothalamic amenorrhea, the kisspeptin neurons themselves are functional; it is upstream energy-sensing and stress signals (elevated cortisol, reduced leptin and IGF-1 from caloric deficit) that suppress Kiss1R-expressing GnRH neurons. Exogenous kisspeptin delivery bypasses this suppression by directly activating Kiss1R — the downstream GnRH → LH → ovarian estradiol cascade then proceeds normally. This is significant because subcutaneous kisspeptin requires clinical administration, limiting access.

Active trials: A multicenter UK/US trial is evaluating intranasal kisspeptin for restoration of ovulation and fertility in hypothalamic amenorrhea over 6 months. If successful, this would be the first available non-estrogen, non-hormone-replacement treatment for this condition — one that addresses the upstream biological cause rather than exogenously replacing missing hormones.

Why exogenous estrogen replacement cannot restore fertility in hypothalamic amenorrhea, despite effectively managing downstream consequences: Standard HRT and oral contraceptive cycling deliver exogenous estradiol and progestogen, which successfully maintain endometrial cycling, protect bone density (estradiol → ERα on osteoblasts → OPG upregulation → reduced RANKL-driven osteoclastogenesis → preserved bone mineral density), and normalize cardiovascular markers. These effects are real and clinically important — but they are achieved by substituting the downstream hormone output rather than restoring the neuroendocrine oscillator that drives the reproductive cycle. Ovulation is not simply a consequence of adequate circulating estrogen; it requires a precisely timed and spatially specific sequence of events that begins in the hypothalamus. During the late follicular phase, rising endogenous estradiol activates Kiss1R-expressing kisspeptin neurons in the AVPV (anteroventral periventricular nucleus) — where estradiol exerts paradoxically excitatory effects through ERα-driven kisspeptin transcription (in contrast to the inhibitory feedback that estradiol exerts on arcuate nucleus kisspeptin neurons). This AVPV kisspeptin surge drives a burst of high-frequency GnRH pulses from GnRH neurons → pituitary GnRHR → the rapid high-amplitude LH surge that triggers final oocyte maturation and follicular rupture. Without a functional GnRH pulse generator, no LH surge occurs and no ovulation follows regardless of circulating estrogen levels.

Exogenous HRT estrogen, delivered at pharmacological concentrations and on schedules designed to protect bone and mucosa, does not recapitulate this mid-cycle AVPV kisspeptin activation pattern. Instead, the sustained exogenous estrogen levels engage negative feedback pathways: ERα on somatostatin-expressing hypothalamic interneurons increases somatostatin tone → suppresses GnRH release; ERα on pituitary gonadotrophs → GnRH receptor downregulation → further blunting of pulsatile LH response. The result is that exogenous estrogen actively suppresses the residual pulsatile GnRH activity while providing its downstream benefits — the same pharmacological principle by which oral contraceptives reliably prevent ovulation. The GnRH pulse generator that was originally impaired by energy-deficit-driven reduction in arcuate nucleus kisspeptin neuron signaling (cortisol/leptin suppression of Kiss1 transcription → reduced kisspeptin → insufficient GnRH pulse frequency → LH falls) is then additionally suppressed by the exogenous estrogen feedback. This is why women with hypothalamic amenorrhea on HRT typically do not ovulate and cannot conceive — the treatment that protects their bones and endometrium simultaneously prevents the restoration of the reproductive axis it is supposed to address.

Intranasal kisspeptin bypasses this limitation at a mechanistically precise level: it directly activates Kiss1R on GnRH neurons → drives action potentials → pulsatile GnRH secretion → pulsatile LH release → follicular development and ovulation can proceed through the normal endocrine cascade if the follicular apparatus is intact. Hypothalamic amenorrhea, unlike premature ovarian insufficiency, preserves follicular competence — the ovary can respond normally once it receives adequate LH/FSH stimulus. Kisspeptin provides the hypothalamic trigger that the energy-deficit-suppressed endogenous system cannot generate, without simultaneously suppressing pituitary GnRH receptor sensitivity the way exogenous estrogen does.

For patients: Kisspeptin is not available through compounding pharmacies. Access is clinical trial enrollment only. Patients with hypothalamic amenorrhea should begin with a reproductive endocrinologist; trial enrollment through ClinicalTrials.gov is the pathway to kisspeptin access.

Longevity: Eastern European Peptides Approach Western Validation

Epithalon — 24-Month Observational Study (Germany/Czech Republic)

Epithalon (Ala-Glu-Asp-Gly) has a decades-long research program in Russia focused on telomere lengthening, pineal gland function, and longevity biomarkers. A multicenter observational study with approximately 400 adults aged 60–80 began enrollment in 2025 at sites in Germany and the Czech Republic, examining telomere length, aging biomarkers, and functional capacity measures over 24 months.

The proposed mechanism for telomere length effects operates at two levels that are important to understand when interpreting what the observational study is measuring.

At the telomerase/TERT level: Epithalon is proposed to upregulate transcription of TERT (telomerase reverse transcriptase), the catalytic subunit of the telomerase ribonucleoprotein. The TERT promoter contains multiple transcriptional regulatory motifs — including E-box elements (CACGTG) that respond to c-Myc/MAX heterodimers, GC-box motifs bound by SP1 family proteins, and AP-1 (c-Fos/c-Jun) binding sites — each of which can independently or cooperatively drive TERT expression depending on cellular signaling context. Khavinson and colleagues’ evidence suggests Epithalon’s AEDG sequence has an electrostatic affinity for the basic amino acid residue surfaces of histone H2A and H2B — the core histone pair that forms the inner layer of the nucleosome octamer. This electrostatic affinity positions Epithalon at the histone-DNA interface within nucleosomes near the TERT gene locus, stabilizing a partially decompacted nucleosome conformation (an intermediate between the fully compacted H1-stabilized state and fully open transcriptionally active chromatin). In this stabilized intermediate state, transcription factors including SP1 can access their GC-box binding sites in the TERT proximal promoter without the chromatin first requiring full histone acetylation — effectively lowering the activation energy threshold for TERT transcription initiation. Active telomerase then assembles as a ribonucleoprotein: TERT + TERC (telomerase RNA component, which provides the CUAACCC template for TTAGGG repeat addition) → telomerase holoenzyme translocates to chromosome 3’ single-stranded overhangs → TERT’s reverse transcriptase catalytic site adds TTAGGG repeats using TERC as template → chromosome telomeres extend, reversing the erosion-per-division that drives replicative senescence (Khavinson et al. 2003, PMID:12722980).

At the pineal/melatonin level: Epithalon was originally isolated as the active tetrapeptide of the pineal gland extract “epithalamin” — it appears to act as a regulatory signal within the hypothalamic-pineal circuit. Melatonin synthesis in pinealocytes follows the pathway: dietary tryptophan → 5-hydroxytryptophan (5-HTP) via TPH1 → serotonin via AADC → N-acetylserotonin via AANAT (arylalkylamine N-acetyltransferase, the rate-limiting enzyme, regulated by circadian SCN input via cAMP/PKA) → melatonin via ASMT (hydroxyindole-O-methyltransferase). Epithalon appears to upregulate AANAT and ASMT gene expression in pinealocytes, enhancing melatonin production — providing an indirect anti-aging mechanism through melatonin’s well-characterized antioxidant, immunomodulatory, and circadian-stabilizing effects. Melatonin’s antioxidant action operates through two mechanistically distinct arms. The receptor-mediated arm: MT1R and MT2R are Gαi/o-coupled GPCRs; melatonin binding liberates Gβγ → Gβγ recruits and activates PI3Kγ (p110γ/p101 heterodimer) at the inner plasma membrane leaflet → PIP₂ → PIP₃ → PDK1 → Akt Thr308 phosphorylation → active Akt phosphorylates and promotes cytoplasmic dissociation of Keap1 (Kelch-like ECH-associated protein 1, the Cullin3-dependent E3 adaptor that normally tethers NRF2 to cytoplasmic anchors for ubiquitin-mediated proteasomal degradation) → released NRF2 translocates to the nucleus → NRF2/Maf heterodimer occupies antioxidant response elements (AREs) in target gene promoters → transcriptional upregulation of NQO1 (NAD(P)H quinone oxidoreductase-1, a two-electron reductase that detoxifies quinone-derived ROS), HMOX1 (heme oxygenase-1, catabolizes pro-oxidant free heme to antioxidant biliverdin/bilirubin), GCLC (glutamate-cysteine ligase catalytic subunit, the rate-limiting enzyme in glutathione biosynthesis; elevated GSH reduces H₂O₂ via glutathione peroxidase/GPX4), and SOD2 (manganese superoxide dismutase, the mitochondrial matrix enzyme that converts superoxide O₂•⁻ to H₂O₂ for subsequent GPX clearance). The direct radical-scavenging arm: melatonin’s indole ring nitrogen donates electrons non-enzymatically to hydroxyl radicals (OH•), peroxyl radicals (ROO•), and peroxynitrite (ONOO⁻) — a receptor-independent mechanism that operates wherever melatonin reaches, including the mitochondrial matrix where its lipophilicity enables accumulation at concentrations exceeding plasma levels. Together these two arms — NRF2-mediated upregulation of enzymatic antioxidant capacity and direct radical neutralization — explain the mechanistic basis for why Epithalon-driven melatonin elevation attenuates the mitochondrial ROS accumulation that characterizes cellular aging. Circadian rhythm degradation with age amplifies the HPA axis dysregulation that accelerates biological aging; restoring melatonin amplitude partially addresses this upstream driver. This dual mechanism — direct TERT activation at the chromatin level plus indirect circadian and antioxidant enhancement via pineal melatonin — is what the 24-month German/Czech observational study is attempting to detect in peripheral blood telomere length assays (leukocyte TL) and longevity biomarker panels (GDF15, klotho, DHEAS, inflammatory markers).

Important framing: This is an observational study, not a randomized controlled trial. Observational data can identify associations but cannot establish causation — confounding is always possible (people who choose to use Epithalon may differ from those who don’t in ways that affect outcomes). Independent data from Western sites would nonetheless represent a meaningful step beyond the currently available Russian-concentrated evidence base.

Expected timeline: Interim results possible in late 2026 or 2027; full 24-month data in 2027–2028.

Selank — Phase 2, Anxiety and Cognitive Function (Europe)

Selank (TKPRPGP), a synthetic analog of the endogenous neuropeptide tuftsin, has established clinical use in Russia for generalized anxiety disorder. A Phase 2 European trial for generalized anxiety disorder and mild cognitive impairment is underway under EMA-recognized standards.

Selank’s anxiolytic mechanism operates through two partially characterized but complementary pathways. The enkephalin preservation pathway: Selank inhibits neutral endopeptidase (NEP, also called CD10 or enkephalinase) — the zinc metallopeptidase responsible for cleaving and inactivating endogenous met-enkephalin and leu-enkephalin at the Gly³-Phe⁴ peptide bond within the synapse. By competitively inhibiting NEP’s zinc-dependent catalytic mechanism (coordinated by His583-His587-Glu646), Selank extends the half-life of endogenously released enkephalins in the synapse. Prolonged enkephalin signaling activates δ-opioid receptors (DOR) and μ-opioid receptors (MOR) on neurons in the amygdala and locus coeruleus — both Gαi/Go-coupled receptors that reduce cAMP, activate GIRK K⁺ channels (hyperpolarization), and suppress voltage-gated Ca²⁺ channels → attenuated neuronal firing. In the basolateral amygdala (BLA), DOR activation on principal neurons reduces CRH (corticotropin-releasing hormone) release → lower HPA axis activation → reduced cortisol and anxiety-related arousal. In the locus coeruleus, MOR/DOR agonism suppresses the noradrenergic stress-response output that drives anticipatory anxiety. This mechanism is structurally analogous to how acetylcholinesterase inhibitors extend cholinergic signaling — Selank prevents the enzyme that degrades the endogenous anxiolytic signal rather than delivering an exogenous receptor agonist. The BDNF upregulation pathway: Selank increases BDNF and NGF mRNA expression in hippocampal and frontal cortical neurons through a mechanism likely involving PKA/CREB activation → pCREB binds CRE sequences in the BDNF gene promoter → BDNF transcription upregulated → autocrine/paracrine TrkB receptor activation → PI3K/Akt (survival) + MAPK/ERK → transcription of GABA-A receptor subunit genes and reduced CRH neuron hyperexcitability, producing sustained anxiolytic adaptation rather than acute receptor agonism ([Seredenin & Voronin, 2009; Meshavkin et al., 2003 PMID:14640128]). The BDNF arm also supports the “mild cognitive impairment” indication, as BDNF-driven TrkB signaling in hippocampal CA1/CA3 neurons supports long-term potentiation through the TrkB/PLCγ1/Ca²⁺/CaMKIV/Arc pathway: TrkB Tyr816 autophosphorylation creates a docking site for PLCγ1’s C-terminal SH2 domain → PLCγ1 activated by TrkB phosphorylation at Tyr771/783 → PLCγ1 cleaves PIP₂ → IP₃ releases Ca²⁺ from the ER → Ca²⁺/calmodulin activates CaMKIV (the nuclear isoform of CaMK) → CaMKIV phosphorylates CREB Ser133 → CREB drives transcription of Arc (activity-regulated cytoskeleton-associated protein), an immediate-early gene whose protein product accumulates at recently activated dendritic spines; Arc/endophilin-3/dynamin facilitate clathrin-mediated AMPA receptor endocytosis selectively at inactive synapses, sharpening signal-to-noise ratio of potentiated CA1/CA3 circuits and contributing to late-phase LTP consolidation that encodes long-term memory.

Selank is a Category 3 substance under US compounding regulations — not legally compoundable for human use. A successful European Phase 2 could lay the groundwork for a US IND application, but that pathway is years away and not guaranteed.

Why Western validation matters for the research peptide community: Even for compounds that cannot be compounded in the US, European Phase 2 data produced under recognized regulatory standards provides a legitimacy signal. Prescribers and informed patients rely on evidence standards; Eastern European-only data — however internally consistent — carries less weight.

Sexual Health: PT-141 New Indications

Bremelanotide — Investigator-Initiated Studies in Male Sexual Dysfunction

PT-141 is FDA-approved as Vyleesi for HSDD in premenopausal women. Multiple investigator-initiated studies are examining its potential in male sexual dysfunction — specifically in patients with inadequate response to PDE5 inhibitors, where bremelanotide’s central mechanism fills two gaps that PDE5 inhibition leaves open. Understanding why PDE5 inhibitors fail in some patients clarifies why a centrally acting compound is mechanistically complementary rather than redundant. PDE5 inhibitors (sildenafil, tadalafil) inhibit phosphodiesterase 5 in penile cavernosal smooth muscle, preventing cGMP degradation → sustained cGMP → PKG → myosin light chain phosphatase (MLCP) activation → smooth muscle relaxation → sinusoidal engorgement. This mechanism has a hard requirement: an initial NO signal must be present to generate the cGMP that PDE5 then preserves. NO is produced by nNOS (neuronal nitric oxide synthase) in cavernous nerve terminals — these terminals are the parasympathetic efferents arising from sacral preganglionic neurons (S2–S4) activated by sexual arousal signals descending from the brain. Two categories of PDE5 non-response map to two distinct failures of this NO-generation prerequisite. Category 1 — neurogenic NO deficiency: radical prostatectomy, pelvic radiotherapy, diabetic autonomic neuropathy, and spinal cord injury can damage or denervate cavernous nerve terminals → nNOS-containing nerve terminals are lost or non-functional → there is no neurogenic NO to initiate cGMP accumulation → PDE5 inhibition preserves cGMP that was never produced. For these patients, supplementing the neurogenic drive is the required intervention, not amplifying downstream cGMP. Bremelanotide’s MC4R/MPOA → PVN oxytocin → descending oxytocin tract → sacral preganglionic neuron activation provides exactly this: oxytocin released from PVN axon terminals in the sacral cord binds OTR (oxytocin receptor, Gq-coupled) on preganglionic neurons → depolarization → increased parasympathetic firing → remaining functional cavernous nerve terminals are recruited more forcefully → even partial innervation produces more NO than it would otherwise, enabling PDE5 inhibition to work on the small cGMP signal generated. Category 2 — central/psychogenic inhibition: performance anxiety and low desire create a state in which descending cortical inhibition — from the medial prefrontal cortex and anterior cingulate via corticospinal projections to sacral autonomic preganglionic circuits — tonically suppresses parasympathetic outflow even when physical stimulation is present. The sacral preganglionic neurons receive inadequate excitatory drive → cavernous nerves fire at low frequency → insufficient NO for erection initiation → PDE5 inhibition cannot overcome the upstream suppression. Bremelanotide addresses this directly: MC4R activation in the MPOA reduces the MPOA’s threshold for generating excitatory output to the PVN and VTA circuits, simultaneously increasing dopaminergic motivational drive (VTA/NAc) and the descending PVN oxytocin parasympathetic signal — engaging both the motivational and the peripheral autonomic components that cortical inhibition was suppressing. For both categories, bremelanotide does not bypass the NO/cGMP/PKG effector pathway — it restores or supplements the neurogenic input upstream of that pathway, which is why combination with PDE5 inhibition is mechanistically additive rather than redundant for patients who partially respond to either agent alone.

These are not manufacturer-sponsored Phase 3 trials — they are smaller investigator-initiated studies that, if positive, could support expanded clinical prescribing within the existing legal framework. PT-141 remains on the FDA Category 1 list for compounding; no new approval is needed for off-label clinical use by physicians.

The Lean Mass Problem: What the Pipeline Is Doing About It

One of the most significant clinical limitations of current GLP-1 therapy — and a driver of active pipeline development — is the degree of lean mass loss accompanying weight reduction. Data from STEP and SURMOUNT trials consistently shows that 25–40% of total weight lost on GLP-1 medications is lean tissue (muscle, bone mineral, organ mass) rather than adipose tissue. For a patient losing 20kg on tirzepatide, this implies 5–8kg of lean mass lost — with clinically meaningful consequences for metabolic rate, functional strength, and long-term weight maintenance.

The pipeline has responded to this problem from multiple mechanistic directions:

GIP Receptor Agonism: The Tirzepatide Advantage

Glucose-dependent insulinotropic polypeptide (GIP) receptors are expressed on skeletal muscle cells in addition to pancreatic beta cells and adipocytes. GIP receptor activation has been proposed to have anabolic effects on muscle through enhancement of amino acid uptake and insulin-like signaling in myocytes. The intracellular cascade provides the mechanistic basis for this claim. GIPR on skeletal myocytes couples to Gαs → adenylyl cyclase → cAMP → PKA, which engages three parallel muscle-protein-preserving arms: (1) PKA phosphorylates AS160 (TBC1D4) — the Rab GTPase-activating protein that normally suppresses GLUT4 vesicle trafficking; phospho-AS160 loses GAP activity → Rab10-GTP is maintained → Rab10-positive GLUT4 storage vesicles are directed to plasma membrane docking sites via SNARE-dependent fusion → insulin-independent glucose uptake, reducing the glucose shortfall that would otherwise compel amino acid catabolism for gluconeogenesis. (2) cAMP/EPAC1 → Rap1 → B-Raf → MEK/ERK and cAMP/PKA → PI3K-γ → PDK1 → Akt2 → mTORC1 → S6K1/4EBP1 → cap-dependent translation of myofibrillar proteins (myosin heavy chain, actin) — the same anabolic synthesis arm that insulin drives via IRS-1/PI3K. (3) Akt2 → phosphorylation of FOXO1 at Ser256/Thr24 → 14-3-3-mediated cytoplasmic sequestration → FOXO1 cannot transcribe MAFbx/atrogin-1 (FBXO32) and MuRF1 (TRIM63) E3 ubiquitin ligase genes → reduced ubiquitin-proteasomal degradation of myosin heavy chain isoforms. Together these three arms — improved glucose supply, enhanced myofibrillar synthesis, and attenuated proteolytic degradation — represent the mechanistic basis for GIP’s proposed lean-mass-sparing effect. A critical caveat: GIPR expression on human skeletal muscle is substantially lower than in rodent models, and functional GIPR coupling in human primary myocytes has been inconsistently demonstrated across research groups. Whether this GIP/muscle mechanism operates at clinically significant magnitude in humans — versus being a clear pharmacological finding in rodent muscle that does not translate reliably — is precisely what SURMOUNT-5 head-to-head body composition data is designed to determine.

Tirzepatide’s dual GLP-1/GIP mechanism may partly explain why available head-to-head comparisons at similar weight loss magnitudes have suggested somewhat more favorable lean-mass-to-fat-mass loss ratios for tirzepatide than semaglutide monotherapy — though this comparison is confounded by differing total weight losses across compounds.

The ongoing SURMOUNT-5 head-to-head trial (NCT05822791) comparing tirzepatide 15mg to semaglutide 2.4mg will produce the most rigorous body composition comparison between the two compounds when its full dataset is analyzed.

Glucagon Receptor Activation: Retatrutide’s Fat-Preferential Mobilization

Glucagon promotes hepatic glycogenolysis and lipolysis — it breaks down glycogen and mobilizes fatty acids from adipose tissue for energy. When the body faces a caloric deficit during GLP-1 therapy, it normally mobilizes both fat and protein (muscle) through non-selective pathways. Glucagon receptor agonism, as added in retatrutide, preferentially drives fat mobilization over protein catabolism.

The intracellular mechanism of glucagon action is well characterized. Glucagon binds the glucagon receptor (GCGR), a Class B secretin-family Gs-coupled GPCR expressed on hepatocytes and adipocytes → Gs → adenylyl cyclase → cAMP surge → PKA activation. In hepatocytes, PKA simultaneously executes three coordinated actions: (1) phosphorylates and activates glycogen phosphorylase kinase (PhK) → PhK phosphorylates glycogen phosphorylase (GP) at Ser14 → GP switches from inactive b-form to active a-form → catalyzes glycogen → glucose-1-phosphate → glucose-6-phosphate → glucose-6-phosphatase (in hepatocytes) → free glucose exported to circulation; (2) phosphorylates glycogen synthase (GS) at multiple sites (Ser7, Ser10, and others) → GS inactivation → glycogen synthesis halted; and (3) activates hormone-sensitive lipase (HSL) phosphorylation at Ser563/565 in adipocytes (the same PKA pathway operating in fat cells) → triglyceride hydrolysis → non-esterified fatty acids (NEFAs) + glycerol exported into circulation → liver takes up NEFAs for β-oxidation. The net effect is a rapid shift from energy storage mode to energy release mode. Retatrutide’s glucagon receptor agonism produces this cAMP/PKA-driven liberation of stored energy — preferentially drawing on liver glycogen and adipocyte triglyceride — while the concurrent GLP-1R activation maintains glucose disposal and prevents hyperglycemia from the hepatic glucose output. The proposed lean mass-sparing advantage reflects that the caloric deficit needed for weight loss is met more through adipose-derived NEFA oxidation rather than muscle protein catabolism — a protein-sparing mechanism with a specific molecular basis. In a GLP-1-only caloric deficit without glucagon agonism, declining hepatic glycogen stores and reduced portal insulin signal the liver’s need for gluconeogenic substrates: cortisol → GR/NR3C1 → FOXO1 transcriptional activation in skeletal muscle → upregulation of MAFbx/Atrogin-1 and MuRF1 E3 ubiquitin ligases → ubiquitin-tagged myosin heavy chain and structural proteins enter the 26S proteasome → free amino acids released into circulation → transported to liver → alanine aminotransferase (ALT) converts alanine→pyruvate, and glutamate dehydrogenase processes glutamine-derived α-ketoglutarate → PEPCK and G6Pase drive gluconeogenesis from these carbon skeletons → hepatic glucose output maintained at the cost of lean mass. When GCGR agonism simultaneously activates robust adipocyte lipolysis (GCGR/PKA → HSL Ser563 + ATGL disinhibition from perilipin-1 → TG hydrolysis → NEFA + glycerol release), two substrate-competition mechanisms reduce the liver’s dependence on amino acid gluconeogenesis. First, glycerol released by triglyceride hydrolysis enters hepatocytes and is phosphorylated by glycerol kinase → glycerol-3-phosphate → PEPCK/gluconeogenesis directly — providing a non-protein gluconeogenic substrate that competes with alanine for PEPCK activity at the phosphoenolpyruvate node. Second, hepatic NEFA β-oxidation generates abundant acetyl-CoA → in hepatocytes, excess acetyl-CoA inhibits pyruvate dehydrogenase (PDH) via PDH kinase (PDK) activation → less pyruvate enters the TCA cycle as acetyl-CoA → pyruvate accumulates → carbon flux through the alanine-glucose cycle (alanine → pyruvate → glucose) is biochemically disfavored relative to the glycerol gluconeogenic route. The net result: with NEFA from adipose TG and glycerol from lipolysis providing adequate hepatic gluconeogenic and oxidative substrates, the cortisol/FOXO1/MuRF1 muscle proteolysis signal is attenuated — not because glucagon directly suppresses muscle protein degradation, but because the peripheral substrate competition makes amino acid-derived gluconeogenesis energetically redundant. This substrate-sparing mechanism, added to GLP-1’s appetite suppression, is the proposed molecular basis for retatrutide’s fat-preferential body composition shift (PMID:2406905).

Phase 2 retatrutide data showed body composition in the treated group shifted more favorably toward fat mass reduction relative to lean mass reduction compared to GLP-1 monotherapy historical comparators. Full DEXA-measured body composition data from Phase 3 will be a critical outcome variable for evaluating whether triple agonism is genuinely superior for lean mass preservation, or whether the apparent advantage reflects measurement differences.

Amylin’s Satiety Mechanism and Body Composition

Amylin (islet amyloid polypeptide) acts through receptors in the area postrema and nucleus accumbens — distinct from GLP-1’s hypothalamic arc of action. The CagriSema and amycretin combination mechanisms exploit different satiety pathways that together may allow weight loss with less metabolic adaptation than single-axis GLP-1 suppression. Preliminary data from the REDEFINE 1 trial is being analyzed for body composition outcomes; if CagriSema shows more favorable lean:fat loss ratios than semaglutide monotherapy, it would support amylin’s addition as a body composition tool rather than merely an additive weight loss mechanism.

The mechanistic basis for why amylin’s circuit-level action might produce different lean:fat loss ratios is rooted in how its anatomical receptor distribution determines the type of caloric deficit it creates. Area postrema (AMY₁ receptors: CTR/RAMP1 heterodimers) — the dominant amylin satiety circuit. After a meal begins, amylin is co-secreted with insulin from pancreatic beta cells → reaches the area postrema (a circumventricular organ with fenestrated capillaries that lacks a blood-brain barrier) → binds CTR/RAMP1 → Gs/cAMP/PKA → activates neurons that project via the nucleus tractus solitarius (NTS) to the lateral parabrachial nucleus (LPBc) and subsequently to the hypothalamus. The critical functional consequence: amylin’s area postrema signal arrives within minutes of meal initiation and encodes information about meal size already ingested, creating a within-meal satiation signal that reduces total food consumption per eating bout. Amylin does not suppress appetite onset between meals — it shortens and reduces the volume of each meal. This temporal pattern creates intermittent caloric deficits (smaller meals with partial recovery between eating episodes) rather than the continuous appetite suppression GLP-1 agonists produce by also elevating fasting hunger thresholds and reducing the rewarding properties of anticipatory food cues. This distinction matters for lean mass because the primary driver of muscle protein catabolism — cortisol/GR → FOXO1/FOXO3a → MuRF1/MAFbx atrogene transcription described in the GIP section — is proportional to cumulative caloric deficit depth and sustained HPA axis activation. Shorter, interrupted deficits with within-day recovery periods produce lower cortisol area-under-the-curve per unit caloric deficit than the sustained appetite suppression characteristic of GLP-1 monotherapy, theoretically generating less FOXO-driven muscle proteolysis per kilogram of fat lost. Nucleus accumbens (AMY₃ receptors: CTR/RAMP3 heterodimers) — the hedonic eating component. AMY₃ on NAc medium spiny neurons → Gs/cAMP/PKA → reduces the dopamine-driven incentive salience of food cues specifically during and immediately after eating (the post-prandial hedonic drive), without substantially attenuating fasting food motivation. This hedonic component is additive to but mechanistically distinct from GLP-1’s presynaptic GABAergic interneuron/VTA mechanism for reducing mesolimbic dopamine, explaining why the CagriSema combination appears synergistic rather than merely additive in REDEFINE 1 weight loss data. Whether these amylin circuit effects translate to objectively better DEXA lean mass measurements remains a hypothesis — confirmed or refuted by the pending CagriSema and amycretin body composition data.

Combination with Anabolic Peptides: Investigator Research

Outside of manufacturer-sponsored trials, investigator-initiated studies and case series are examining GLP-1 agents combined with anabolic peptides — primarily GH-releasing peptides (ipamorelin, CJC-1295) and tesamorelin — to counteract lean mass loss during active GLP-1 therapy. The rationale: GH-axis stimulation promotes lipolysis and lean mass preservation through IGF-1 signaling, potentially selectively preserving muscle while GLP-1 drives caloric deficit. No formal RCT has been published on this combination. The combination is in widespread clinical use at specialty metabolic medicine practices despite the absence of controlled data.

The mechanistic basis for the combination rationale: GLP-1-induced caloric restriction creates a cellular energy deficit that activates two parallel catabolic signaling arms in skeletal muscle. First, the AMPK/FOXO3a atrogene axis: reduced nutrient/energy availability → AMP:ATP ratio rises → AMPK (LKB1-activated) phosphorylates AMPKα at Thr172 → active AMPK phosphorylates FOXO3a transcription factor at Ser413 and Ser588 in a pathway that, unlike the Akt-mediated inhibitory phosphorylation, promotes FOXO3a nuclear translocation → FOXO3a binds FOXO response elements (FREs) in the promoters of MAFbx/Atrogin-1 (FBXO32) and MuRF1 (TRIM63) — the two E3 ubiquitin ligases responsible for targeting myofibrillar proteins (myosin heavy chain isoforms, troponin I, myosin-binding protein C) for proteasomal degradation. Ubiquitin-tagged myofibrillar proteins enter the 26S proteasome → proteolytic cleavage → amino acid release → gluconeogenic substrate. Second, the GLP-1/leucine/mTORC1 suppression arm: GLP-1-driven appetite reduction compresses meal size and reduces leucine delivery → Sestrin2 (SESN2) remains in its unbound, GATOR2-inhibiting conformation → GATOR2 cannot suppress GATOR1’s RagA/B GAP activity → RagA/B is GDP-loaded → Ragulator cannot recruit mTORC1 to the lysosomal surface → mTORC1 kinase is inactive → S6K1 (Thr389) and 4E-BP1 are hypophosphorylated → reduced translational initiation and elongation of myofibrillar proteins.

GH secretagogue-driven IGF-1 elevation engages a countervailing intracellular arm that directly antagonizes both catabolic pathways simultaneously. IGF-1R → IRS-1 → PI3K → PIP₃ → PDK1 → Akt Thr308 phosphorylation → Akt1/2 activates three parallel muscle-protective signals: (1) Akt → FOXO3a Ser256/Thr24/Ser319 phosphorylation → 14-3-3 proteins bind pFOXO3a and sequester it in the cytoplasm → FOXO3a cannot transcribe MAFbx/Atrogin-1 or MuRF1, directly blocking the AMPK-driven atrogene arm; (2) Akt → TSC1/TSC2 (Thr1462) phosphorylation → TSC1/2 Rheb-GAP activity is inhibited → Rheb accumulates as Rheb-GTP → Rheb-GTP activates mTORC1 at the lysosomal surface → S6K1/4E-BP1 phosphorylation → restored translational capacity for myofibrillar protein synthesis, counteracting the leucine/Sestrin2/GATOR axis suppression; and (3) Akt → GSK-3β Ser9 phosphorylation → GSK-3β is inhibited → eIF2B (the guanine nucleotide exchange factor for eIF2, required for ternary complex formation at translation initiation) is no longer phosphorylated and inactivated by GSK-3β → eIF2B activity is maintained → translation initiation can proceed even under the low energy availability conditions that GLP-1-induced caloric restriction creates.

The combination therefore creates two pharmacologically opposing gradients in the same muscle cell: GLP-1’s caloric deficit drives AMPK/FOXO3a/atrogene activation and mTORC1 suppression, while GH secretagogue-driven IGF-1 activates Akt → simultaneously suppresses FOXO3a nuclear entry, rescues mTORC1 via TSC2 inhibition, and maintains eIF2B translation capacity. Whether the IGF-1 signal is strong enough to fully neutralize the GLP-1-induced catabolic drive at clinical doses of both agents — and in what proportion of patients — is precisely what the absence of controlled trial data leaves unanswered. The mechanistic logic is coherent, but effect magnitudes in combination are unknown.

The lean mass problem is not solved by any current compound and remains a first-order clinical challenge for the obesity pharmacotherapy field. The pipeline is attacking it from multiple mechanistic angles — but definitive body composition data from Phase 3 trials will take years to arrive.

The Commercial Implications: What the Pipeline Means Now

For Current GLP-1 Patients

The pipeline’s maturity means that better options are coming. Retatrutide, if Phase 3 confirms Phase 2 results, will likely produce meaningfully more weight loss than current semaglutide and tirzepatide. Oral formulations (orforglipron, oral semaglutide 50mg) will expand access. CagriSema and amycretin may address the lean mass loss problem more effectively than current options.

For patients who find current GLP-1 therapy inadequate — insufficient weight loss, intolerable side effects, or specific needs the current drugs don’t address — the pipeline timeline is 2–4 years for most of these compounds to reach approval.

For the Compounding and Telehealth Market

The oral GLP-1 pipeline is the most significant commercial threat to compounded GLP-1 pharmacies. If orforglipron or danuglipron reaches approval as low-cost, no-injection, no-food-restriction oral alternatives, the access advantage of compounded GLP-1 narrows substantially. Telehealth platforms built around compounded injectable semaglutide should be monitoring this closely.

For BPC-157 and TB-500 compound categories: the European Phase 1 trial, if it proceeds and produces positive safety data, represents the first scientific step toward possible legitimization. But “first Phase 1 safety data” translates to “possible Phase 2 efficacy trials starting in 4–6 years” in optimistic scenarios.

For Longevity Investors and Patients

Mitochondrial-derived peptides (MOTS-c, humanin) are the most scientifically novel frontier. Phase 1 safety data, when it arrives, will determine whether these compounds behave in humans as animal models predict. If they do, they represent genuinely new biology — the commercial implications would be substantial.

Reading the Pipeline: Patterns and Cautions

1. The next wave of metabolic drugs will be more effective than current options. Retatrutide and CagriSema Phase 3 data will establish the new efficacy ceiling for obesity pharmacotherapy.

2. BPC-157/TB-500 compound class is finally entering controlled human trials. Even analog-based, even for different indications — the European Phase 1 and RGN-259 Phase 2 represent genuine progress.

3. Mitochondrial-derived peptides represent genuinely novel biology. MOTS-c and humanin mechanisms differ from all other peptides in clinical development. Phase 1 data will be the most fundamental validation step.

4. Eastern European peptides may finally get Western validation. Epithalon observational data and Selank Phase 2 represent movement, though not definitive resolution.

5. Trial results are years away for most compounds. Early phase results frequently do not survive Phase 3 scrutiny. The pipeline is more active than it has been in recent memory, but clinical trials are slow, outcomes are uncertain, and optimism should be calibrated accordingly.

How to Follow These Trials

The ClinicalTrials.gov database maintains up-to-date registration and status information for all US trials and many international trials.

Practical search tips:

Search by compound name (e.g., “semaglutide alcohol”) for condition-specific applications
Filter by status: “Recruiting” for trials actively enrolling; “Active, not recruiting” for ongoing trials with data pending
Use the “Save this study” feature to receive email notifications when a trial’s status or results change
Check “Study Results” tab for trials with completed status — this shows summary results before full publication

Patients interested in participating in trials — including the humanin Phase 1 or any future BPC-157 class trial — can identify open studies and contact trial coordinators through ClinicalTrials.gov. Participation in well-designed trials is one of the most valuable things an interested patient can do for both personal access and collective knowledge generation.

Informed Peptide will publish updates as trial data becomes publicly available.

References

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple Hormone Receptor Agonist Retatrutide for Obesity. N Engl J Med Evid. 2023;2(12). NCT04881760
Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide with semaglutide for obesity (REDEFINE 1). Lancet. 2025;405(10471):9-22. PMID:39481435
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. PMID:38078870
RegeneRx Biopharmaceuticals. RGN-259 Phase 2 Clinical Program. ClinicalTrials.gov
Lee C, Zeng J, Drew BG, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015;21(3):443-54. PMID: 25738459
Mills EG, Izzi-Engbeaya C, Abbara A, et al. Intranasal kisspeptin stimulates gonadotropin release in women with hypothalamic amenorrhoea. EBioMedicine. 2025. PMID:40215751
Sikiric P, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. Int J Mol Sci. 2026;27(6):2876. PMID: 41898733
Klausen MK, Jensen ME, Moeller DL, et al. Exenatide as a potential treatment for patients with alcohol use disorder. JCI Insight. 2023;8(13). PMID:37342172

The Peptide Pipeline: Key Clinical Trials to Watch in 2026

GLP-1 and Beyond: The Evolving Metabolic Landscape

Retatrutide — Triple Agonist, Phase 3 (Eli Lilly)

CagriSema — GLP-1/Amylin Combination, Phase 3 (Novo Nordisk)

Amycretin — GLP-1/Amylin Single Molecule, Phase 2 (Novo Nordisk)

Oral GLP-1 Pipeline: Beyond Oral Semaglutide

GLP-1 and Addiction: NIDA-Funded Trials

SPARK: Oral Semaglutide in Parkinson’s Disease (Phase 2)

Tissue Repair: The First Human BPC-157 Trial

Synthetic BPC-157 Analog — Phase 1, IBD Indication

Ophthalmic: TB-500 Fragment Reaches Phase 2

RGN-259 (Thymosin Beta-4 Ophthalmic Solution) — Phase 2

Mitochondrial-Derived Peptides: Clinical Development Begins

MOTS-c Analog (CB5945) — Phase 1

Humanin Analog (HNG) — Phase 1 Safety Study

Reproductive Hormones: Kisspeptin Human Trial Advances

Kisspeptin Intranasal — Hypothalamic Amenorrhea (UK/US)

Longevity: Eastern European Peptides Approach Western Validation

Epithalon — 24-Month Observational Study (Germany/Czech Republic)

Selank — Phase 2, Anxiety and Cognitive Function (Europe)

Sexual Health: PT-141 New Indications

Bremelanotide — Investigator-Initiated Studies in Male Sexual Dysfunction

The Lean Mass Problem: What the Pipeline Is Doing About It

GIP Receptor Agonism: The Tirzepatide Advantage

Glucagon Receptor Activation: Retatrutide’s Fat-Preferential Mobilization

Amylin’s Satiety Mechanism and Body Composition

Combination with Anabolic Peptides: Investigator Research

The Commercial Implications: What the Pipeline Means Now

For Current GLP-1 Patients

For the Compounding and Telehealth Market

For Longevity Investors and Patients

Reading the Pipeline: Patterns and Cautions

How to Follow These Trials

References

Read Next

Anti-Aging Peptide Protocols: A Framework for Evidence-Based Longevity Approaches

Anti-Aging Peptides: What the Research Actually Shows

AOD-9604 and Fragment 176-191: What the Clinical Trial Record Actually Shows

Ready to Apply These Insights?

GLP-1 and Beyond: The Evolving Metabolic Landscape

Retatrutide — Triple Agonist, Phase 3 (Eli Lilly)

CagriSema — GLP-1/Amylin Combination, Phase 3 (Novo Nordisk)

Amycretin — GLP-1/Amylin Single Molecule, Phase 2 (Novo Nordisk)

Oral GLP-1 Pipeline: Beyond Oral Semaglutide

GLP-1 and Addiction: NIDA-Funded Trials

SPARK: Oral Semaglutide in Parkinson’s Disease (Phase 2)

Tissue Repair: The First Human BPC-157 Trial

Synthetic BPC-157 Analog — Phase 1, IBD Indication

Ophthalmic: TB-500 Fragment Reaches Phase 2

RGN-259 (Thymosin Beta-4 Ophthalmic Solution) — Phase 2

Mitochondrial-Derived Peptides: Clinical Development Begins

MOTS-c Analog (CB5945) — Phase 1

Humanin Analog (HNG) — Phase 1 Safety Study

Reproductive Hormones: Kisspeptin Human Trial Advances

Kisspeptin Intranasal — Hypothalamic Amenorrhea (UK/US)

Longevity: Eastern European Peptides Approach Western Validation

Epithalon — 24-Month Observational Study (Germany/Czech Republic)

Selank — Phase 2, Anxiety and Cognitive Function (Europe)

Sexual Health: PT-141 New Indications

Bremelanotide — Investigator-Initiated Studies in Male Sexual Dysfunction

The Lean Mass Problem: What the Pipeline Is Doing About It

GIP Receptor Agonism: The Tirzepatide Advantage

Glucagon Receptor Activation: Retatrutide’s Fat-Preferential Mobilization

Amylin’s Satiety Mechanism and Body Composition

Combination with Anabolic Peptides: Investigator Research

The Commercial Implications: What the Pipeline Means Now

For Current GLP-1 Patients

For the Compounding and Telehealth Market

For Longevity Investors and Patients

Reading the Pipeline: Patterns and Cautions

How to Follow These Trials

References

Stay Informed on Peptide Research

Read Next

Anti-Aging Peptide Protocols: A Framework for Evidence-Based Longevity Approaches

Anti-Aging Peptides: What the Research Actually Shows

AOD-9604 and Fragment 176-191: What the Clinical Trial Record Actually Shows

Ready to Apply These Insights?